Pfizer (PFE) Should Benefit From Encouraging In-Vitro COVID-19 Vaccine Data for Brazil Strain - Goldman Sachs
Tweet Send to a Friend
Goldman Sachs analyst Terence Flynn reiterated a Neutral rating and $41.00 price target on Pfizer (NYSE: PFE) after investigators published ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
